Tea beverage in chemoprevention and chemotherapy of prostate cancer

Acta Pharmacologica Sinica

Volumn 28, Issue 9, 2007, Pages 1392-1408

  Siddiqui, Imtiaz A ^a   Saleem, Mohammad ^a   Adhami, Vaqar M ^a   Asim, Mohammad ^a   Mukhtar, Hasan ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

( )epicatechin; ( )epigallocatechin 3 gallate; Androgen receptor; Apoptosis; Clinical studies; Epidemiology; Green tea; PSA; Tumor xenograft

Indexed keywords

ANTINEOPLASTIC AGENT; CATECHIN; EPICATECHIN; EPICATECHIN 3 GALLATE; EPIGALLOCATECHIN; EPIGALLOCATECHIN GALLATE; FLAVONOID; FLAVONOL DERIVATIVE; GALLIC ACID; GREEN TEA EXTRACT; GUANOSINE TRIPHOSPHATE; METHYLXANTHINE; PLACEBO; POLYPHENOL; PROSTATE SPECIFIC ANTIGEN; QUINIC ACID; THEANINE; THEARUBIGIN; THEFLAVIN; THEOGALLIN; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DIET THERAPY; DRUG ACTIVITY; DRUG MECHANISM; FATIGUE; HUMAN; INSOMNIA; NONHUMAN; NUTRITIONAL REQUIREMENT; PROSTATE CANCER; REVIEW; RISK REDUCTION; TEA; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTICARCINOGENIC AGENTS; CLINICAL TRIALS AS TOPIC; FLAVONOIDS; HUMANS; MALE; PHENOLS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TEA;

EID: 34548401602     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2007.00693.x     Document Type: Review

References (150)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007 57 : 43 66.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005 55 : 74 108.
3. Sim HG, Cheng CW. Changing demography of prostate cancer in Asia. Eur J Cancer 2005 41 : 834 45.
4. Platz EA, Giovannucci E. The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. J Steroid Biochem Mol Biol 2004 92 : 237 53.
5. Lowe JF, Frazee LA. Update on prostate cancer chemoprevention. Pharmacotherapy 2006 26 : 353 9.
6. Sikka SC. Role of oxidative stress response elements and anti-oxidants in prostate cancer pathobiology and chemoprevention -a mechanistic approach. Curr Med Chem 2003 10 : 2679 92.
7. Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J, et al. Human prostate cancer risk factors. Cancer 2004 101 : 2371 490.
8. Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000 85 : 60 7.
9. Terry PD, Rohan TE, Wolk A. Intakes of fish and marine fatty acids and the risks of cancers of the breast and prostate and of other hormone-related cancers: a review of the epidemiologic evidence. Am J Clin Nutr 2003 77 : 532 43.
10. Rohrmann S, Platz EA, Kavanaugh CJ, Thuita L, Hoffman SC, Helzlsouer KJ. Meat and dairy consumption and subsequent risk of prostate cancer in a US cohort study. Cancer Causes Control 2007 18 : 41 50.
11. Jani AB, Hellman S, Jani AB, Hellman S. Early prostate cancer: clinical decision-making. Lancet 2003 361 : 1045 53.
12. Lamson DW, Brignall MS. Natural agents in the prevention of cancer, part two: preclinical data and chemoprevention for common cancers. Altern Med Rev 2001 6 : 167 87.
13. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 2003 3 : 768 80.
14. Schuurman AG, Goldbohm RA, Brants HA, van den Brandt PA. A prospective cohort study on intake of retinol, vitamins C and E, and carotenoids and prostate cancer risk [Netherlands]. Cancer Causes Control 2002 13 : 573 82.
15. Klein EA. Selenium: epidemiology and basic science. J Urol 2004 171 : S50 3 discussion S53.
16. Siddiqui IA, Adhami VM, Saleem M, Mukhtar H. Beneficial effects of tea and its polyphenols against prostate cancer. Mol Nutr Food Res 2006 50 : 130 43.
17. Khan N, Afaq F, Mukhtar H. Apoptosis by dietary factors: the suicide solution for delaying cancer growth. Carcinogenesis 2007 28 : 233 9.
18. Gupta S, Ahmad N, Mohan RR, Husain MM, Mukhtar H. Prostate cancer chemoprevention by green tea: in vitro and in vivo inhibition of testosterone-mediated induction of ornithine decarboxylase. Cancer Res 1999 59 : 2115 20.
19. Siddiqui IA, Afaq F, Adhami VM, Mukhtar H. Prevention of prostate cancer through custom tailoring of chemopreventive regimen. Chem Biol Interact 2007 Mar 12 (Epub ahead of print).
20. Lee KW, Lee HJ. The roles of polyphenols in cancer chemo-prevention. Biofactors 2006 26 : 105 21.
21. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 2006 71 : 1397 421.
22. Tsao AS, Kim ES, Hong WK. Chemoprevention of cancer. CA Cancer J Clin 2004 54 : 150 80.
23. Sarkar FH, Li Y. The role of isoflavones in cancer chemoprevention. Front Biosci 2004 9 : 2714 24.
24. Jian L, Xie LP, Lee AH, Binns CW. Protective effect of green tea against prostate cancer: a case-control study in southeast China. Int J Cancer 2004 108 : 130 5.
25. Klein EA, Thompson IM. Update on chemoprevention of prostate cancer. Curr Opin Urol 2004 14 : 143 9.
26. Thompson IM, Ankerst D P, Chi C, Goodman PJ, Tangen CM, Lucia MS, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006 98 : 529 34.
27. Lieberman R. Evidence-based medical perspectives: the evolving role of PSA for early detection, monitoring of treatment response, and as a surrogate end point of efficacy for interventions in men with different clinical risk states for the prevention and progression of prostate cancer. Am J Ther 2004 11 : 501 6.
28. Yamamoto T, Hsu S, Lewis J, Wataha J, Dickinson D, Singh B, et al. Green tea polyphenol causes differential oxidative environments in tumor versus normal epithelial cells. J Pharmacol Exp Ther 2003 307 : 230 6.
29. Chung FL, Schwartz J, Herzog CR, Yang YM. Tea and cancer prevention: studies in animals and humans. J Nutr 2003 133 : 3268S 3274S.
30. Siddiqui IA, Afaq F, Adhami VM, Ahmad N, Mukhtar H. Antioxidants of the beverage tea in promotion of human health. Antioxid Redox Signal 2004 6 : 571 82.
31. Rumpler W, Seale J, Clevidence B, Judd J, Wiley E, Yamamoto S, et al. Oolong tea increases metabolic rate and fat oxidation in men. J Nutr 2001 131 : 2848 52.
32. Yang CS. Tea and health, Nutrition 1999 15 : 946 9.
33. Raederstorff DG, Schlachter MF, Elste V, Weber P. Effect of EGCG on lipid absorption and plasma lipid levels in rats. J Nutr Biochem 2003 14 : 326 32.
34. Tokunaga S, White IR, Frost C, Tanaka K, Kono S, Tokudome S, et al. Green tea consumption and serum lipids and lipoproteins in a population of healthy workers in Japan. Ann Epidemiol 2002 12 : 157 65.
35. Babu PV, Sabitha KE, Srinivasan P, Shyamaladevi CS. Green tea attenuates diabetes induced Maillard-type fluorescence and collagen cross-linking in the heart of streptozotocin diabetic rats. Pharmacol Res 2007 55 : 433 40.
36. Tsuneki H, Ishizuka M, Terasawa M, Wu JB, Sasaoka T, Kimura I. Effect of green tea on blood glucose levels and serum proteomic patterns in diabetic (db/db) mice and on glucose metabolism in healthy humans. BMC Pharmacol 2004 4 : 18.
37. Yang CS, Wang ZY. Tea and cancer. Journal of National Cancer Institute 1993 85 : 1038 49.
38. Dufresne CJ, Farnworth ER. A review of latest research findings on the health promotion properties of tea. J Nutr Biochem 2001 12 : 404 21.
39. Ahmad N, Feyes DK, Nieminen AL, Agarwal R, Mukhtar H. Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J Natl Cancer Inst 1997 89 : 1881 6.
40. Liao S, Kao YH, Hiipakka RA. Green tea: biochemical and biological basis for health benefits. Vitam Horm 2001 62 : 1 94.
41. Yokozawa T, Dong E. Influence of green tea and its three major components upon low-density lipoprotein oxidation. Exp Toxicol Pathol 1997 49 : 329 35.
42. Kao YH, Hiipakka RA, Liao S. Modulation of endocrine systems and food intake by green tea epigallocatechin gallate. Endocrinology 2000 141 : 980 7.
43. Beltz LA, Bayer DK, Moss AL, Simet IM. Mechanisms of cancer prevention by green and black tea polyphenols. Anticancer Agents Med Chem 2006 6 : 389 406.
44. Liang YC, Lin-Shiau SY, Chen CF, Lin JK. Inhibition of cyclin-dependent kinases 2 and 4 activities as well as induction of Cdk inhibitors p21 and p27 during growth arrest of human breast carcinoma cells by (-)-epigallocatechin-3- gallate. J Cell Biochem 1999 75 : 1 12.
45. Ahmad N, Adhami VM, Gupta S, Cheng P, Mukhtar H. Role of the retinoblastoma (pRb)-E2F/DP pathway in cancer chemo-preventive effects of green tea polyphenol epigallocatechin-3-gallate. Arch Biochem Biophys 2002 398 : 125 31.
46. Afaq F, Adhami VM, Ahmad N, Mukhtar H. Inhibition of ultraviolet B-mediated activation of nuclear factor kappaB in normal human epidermal keratinocytes by green tea Constituent (-)-epigallocatechin-3-gallate. Oncogene 2003 22 : 1035 44.
47. Yang GY, Liao J, Kim K, Yurkow EJ, Yang CS. Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols. Carcinogenesis 1998 19 : 611 16.
48. Chung JY, Huang C, Meng X, Dong Z, Yang CS. Inhibition of activator protein 1 activity and cell growth by purified green tea and black tea polyphenols in H-ras-transformed cells: structure-activity relationship and mechanisms involved. Cancer Res 1999 59 : 4610 17.
49. Yang CS, Maliakal P, Meng X. Inhibition of carcinogenesis by tea. Annu Rev Pharmacol Toxicol 2002 42 : 25 54.
50. Kranse R, Dagnelie PC, van Kemenade MC, de Jong FH, Blom JH, Tijburg LB, et al. Dietary intervention in prostate cancer patients: PSA response in a randomized double-blind placebo-controlled study. Int J Cancer 2005 113 : 835 40.
51. Pu YS, Chiang HS, Lin CC, Huang CY, Huang KH, Chen J. Changing trends of prostate cancer in Asia. Aging Male 2004 7 : 120 32.
52. Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000 85 : 60 7.
53. Mohan RR, Challa A, Gupta S, Bostwick DG, Ahmad N, Agarwal R, et al. Overexpression of ornithine decarboxylase in prostate cancer and prostatic fluid in humans. Clin Cancer Res 1999 5 : 143 7.
54. Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ, et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996 56 : 4096 102.
55. Gupta S, Hastak K, Ahmad N, Lewin JS, Mukhtar H. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci USA 2001 98 : 10350 5.
56. Adhami VM, Ahmad N, Mukhtar H. Molecular targets for green tea in prostate cancer prevention. J Nutr 2003 133 : 2417S 24S.
57. Caporali A, Davalli P, Astancolle S, D'Arca D, Bettuzzi S, et al. The chemopreventive action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin over-expression. Carcinogenesis 2004 25 : 2217 24.
58. Debruyne F. Hormonal therapy of prostate cancer. Semin Urol Oncol 2002 20 : 4 9.
59. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate, 1941. J Urol 2002 168 : 9 12.
60. Fluchter SH, Weiser R, Gamper C. The role of hormonal treatment in prostate cancer. Recent Results Cancer Res 2007 175 : 211 37.
61. Long BJ, Grigoryev DN, Nnane I P, Liu Y, Ling YZ, Brodie AM. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer. Cancer Res 2000 60 : 6630 40.
62. Hiipakka RA, Zhang HZ, Dai W, Dai Q, Liao S. Structure-activity relationships for inhibition of human 5alpha-reductases by polyphenols. Biochem Pharmacol 2002 63 : 1165 76.
63. Koivisto P, Kolmer M, Visakorpi T, Kallioniemi OP. Androgen receptor gene and hormonal therapy failure of prostate cancer. Am J Pathol 1998 152 : 1 9.
64. Ettinger SL, Sobel R, Whitmore TG, Akbari M, Bradley DR, Gleave ME, et al. Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res 2004 64 : 2212 21.
65. Haapala K, Kuukasjarvi T, Hyytinen E, Rantala I, Helin HJ, Koivisto PA. Androgen receptor amplification is associated with increased cell proliferation in prostate cancer. Hum Pathol 2007 38 : 474 8.
66. Palmberg C, Koivisto P, Kakkola L, Tammela TL, Kallioniemi OP, Visakorpi T. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol 2000 164 : 1992 5.
67. Ren F, Zhang S, Mitchell SH, Butler R, Young CY. Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells. Oncogene. 2000 9 : 1924 32.
68. Takane KK, McPhaul MJ. Functional analysis of the human androgen receptor promoter. Mol Cell Endocrinol 1996 119 : 83 93.
69. Chen S, Supakar PC, Vellanoweth RL, Song CS, Chatterjee B, Roy AK. Functional role of a conformationally flexible homopurine/homopyrimidine domain of the androgen receptor gene promoter interacting with Sp1 and a pyrimidine single strand DNA-binding protein. Mol Endocrinol 1997 11 : 3 15.
70. Yuan H, Gong A, Young CY. Involvement of transcription factor Sp1 in quercetin-mediated inhibitory effect on the androgen receptor in human prostate cancer cells. Carcinogenesis 2005 26 : 793 801.
71. Philipsen S, Suske G. A tale of three fingers: the family of mammalian Sp/XKLF transcription factors. Nucleic Acids Res 1999 27 : 2991 3000.
72. Peracaula R, Tabares G, Royle L, Harvey DJ, Dwek RA, Rudd PM, et al. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins. Glycobiology 2003 13 : 457 70.
73. Miller N, Smolkin ME, Bissonette E, Theodorescu D. Undetect-able prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy. Cancer 2005 103 : 2499 506.
74. Grossfeld GD, Carroll PR. Prostate cancer early detection: a clinical perspective. Epidemiol Rev 2001 23 : 173 80.
75. Yuan Q, Ray RM, Viar MJ, Johnson LR. Polyamine regulation of ornithine decarboxylase and its antizyme in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 2001 280 : G130 8.
76. Ray RM, McCormack SA, Covington C, Viar MJ, Zheng Y, Johnson LR. The requirement for polyamines for intestinal epithelial cell migration is mediated through Rac1. J Biol Chem 2003 278 : 13039 46.
77. Poulin R, Pelletier G, Pegg AE. Induction of apoptosis by excessive polyamine accumulation in ornithine decarboxylase-over-producing L1210 cells. Biochem J 1995 311 : 723 7.
78. Tobias KE, Kahana C. Exposure to ornithine results in excessive accumulation of putrescine and apoptotic cell death in ornithine decarboxylase-overproducing mouse myeloma cells. Cell Growth Differ 1995 6 : 1279 85.
79. Auvinen M, Laine A, Paasinen-Sohns A, Kangas A, Kangas L, Saksela O, et al. Human Ornithine decarboxylase-overproducing NIH3T3 cells induce rapidly growing, highly vascularized tumors in nude mice. Cancer Res 1997 57 : 3016 25.
80. Kubota S, Kiyosawa H, Nomura Y, Yamada T, Seyama Y. Ornithine decarboxylase overexpression in mouse 10T1/2 fibroblasts: cellular transformation and invasion. J Natl Cancer Inst 1997 89 : 567 71.
81. Palavan-Unsal N, Aloglu-Senturk SM, Arsan D. The function of polyamine metabolism in prostate cancer. Exp Oncol 2006 28 : 178 86.
82. Zeegers MP, Ostrer H. Genes in the polyamine biosynthesis pathway may be involved in prostate cancer susceptibility. Future Oncol 2005 1 : 683 8.
83. Ahmad N, Gilliam AC, Katiyar SK, O'Brien TG, and Mukhtar H. A definitive role of ornithine decarboxylase in photocarcinogenesis. Am J Pathol 2001 159 : 885 92.
84. Kadmon D. Chemoprevention in prostate cancer: the role of difluoromethylornithine [DFMO]. J Cell Biochem 1992 16H : 122 7.
85. Heston WD. Prostatic polyamines and polyamine targeting as a new approach to therapy of prostatic cancer. Cancer Surv 1991 11 : 217 38.
86. Bachrach U and Wang YC. Cancer therapy and prevention by green tea: role of ornithine decarboxylase. Amino Acids 2002 22 : 1 13.
87. Bai G, Kasper S, Matusik RJ, Rennie PS, Moshier JA, Krongrad A. Androgen regulation of the human ornithine decarboxylase promoter in prostate cancer cells. J Androl 1998 19 : 127 35.
88. Asadi F, Faraj M, Malakouti S, Kukreja SC. Effect of parathyroid hormone related protein, and dihydrotestosterone on proliferation and ornithine decarboxylase mRNA in human prostate cancer cell lines. Int Urol Nephrol 2001 33 : 417 22.
89. Paul B, Hayes CS, Kim A, Athar M, Gilmour SK. Elevated polyamines lead to selective induction of apoptosis and inhibition of tumorigenesis by (-)-epigallocatechin-3-gallate (EGCG) in ODC/Ras transgenic mice. Carcinogenesis. 2005 26 : 119 24.
90. Wang SI, Mukhtar H. Gene expression profile in human prostate LNCaP cancer cells by (-)epigallocatechin-3-gallate. Cancer Lett 2002 182 : 43 51.
91. Meyers FJ, Gumerlock PH, Chi SG, Borchers H, Deitch AD, deVere White RW. Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors. Cancer 1998 83 : 2534 9.
92. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, et al. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993 85 : 1657 69.
93. Gupta S, Ahmad N, Nieminen AL, Mukhtar H. Growth inhibition, cell-cycle dysregulation, and induction of apoptosis by green tea constituent [-]-epigallocatechin-3-gallate in androgen-sensitive and androgen-insensitive human prostate carcinoma cells. Toxicol Appl Pharmacol 2000 164 : 82 90.
94. Hastak K, Gupta S, Ahmad N, Agarwal MK, Agarwal ML, Mukhtar H. Role of p53 and NF-kappaB in epigallocatechin-3-gallate induced apoptosis of LNCaP cells. Oncogene 2003 22 : 4851 9.
95. Van Cruchten S, Van Den Broeck W. Morphological and biochemical aspects of apoptosis, oncosis and necrosis. Anat Histol Embryol 2002 31 : 214 23.
96. Proskuryakov SY, Konoplyannikov AG, Gabai VL. Necrosis: a specific form of programmed cell death Exp Cell Res 2003 283 : 1 16.
97. Kroemer G, Petit P, Zamzami N, Vayssiere JL, Mignotte B. The biochemistry of programmed cell death. FASEB J 1995 9 : 1277 87.
98. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001 411 : 342 8.
99. Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996 28 : 251 65.
100. Tang DG, Porter AT. Target to apoptosis: a hopeful weapon for prostate cancer. Prostate 1997 32 : 284 93.
101. Hussain M, Banerjee M, Sarkar FH, Djuric Z, Pollak MN, Doerge D, et al. Soy isoflavones in the treatment of prostate cancer. Nutr Cancer 2003 47 : 111 7.
102. Chiao JW, Wu H, Ramaswamy G, Conaway CC, Chung FL, Wang L, et al. Ingestion of an isothiocyanate metabolite from cruciferous vegetables inhibits growth of human prostate cancer cell xenografts by apoptosis and cell cycle arrest. Carcinogenesis 2004 25 : 1403 8.
103. Saleem M, Kweon MH, Yun JM, Adhami VM, Khan N, Syed DN, et al. A novel dietary triterpene Lupeol induces fas-mediated apoptotic death of androgen-sensitive prostate cancer cells and inhibits tumor growth in a xenograft model. Cancer Res 2005 65 : 11203 13.
104. Stuart EC, Scandlyn MJ, Rosengren RJ. Role of epigallocatechin gallate (EGCG) in the treatment of breast and prostate cancer. Life Sci 2006 79 : 2329 36.
105. Chung LY, Cheung TC, Kong SK, Fung KP, Choy YM, Chan ZY, et al. Induction of apoptosis by green tea catechins in human prostate cancer DU145 cells. Life Sci 2001 68 : 1207 14.
106. Huang S, New L, Pan Z, Han J, Nemerow GR. Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38alpha mitogen-activated protein kinase activity. J Biol Chem 2000 275 : 12266 72.
107. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980 284 : 67 8.
108. Garbisa S, Sartor L, Biggin S, Salvato B, Benelli R, Albini A. Tumor gelatinases and invasion inhibited by the green tea flavanol epigallocatechin-3-gallate. Cancer 2001 91 : 822 32.
109. Jung YD, Ellis LM. Inhibition of tumour invasion and angio-genesis by epigallocatechin gallate (EGCG), a major component of green tea. Int J Exp Pathol 2001 82 : 309 16.
110. Singh AK, Seth P, Anthony P, Husain MM, Madhavan S, Mukhtar H, et al. Green tea constituent epigallocatechin-3-gallate inhibits angiogenic differentiation of human endothelial cells. Arch Biochem Biophys 2002 401 : 29 37.
111. Rodriguez SK, Guo W, Liu L, Band MA, Paulson EK, Meydani M. Green tea catechin, epigallocatechin-3-gallate, inhibits vascular endothelial growth factor angiogenic signaling by disrupting the formation of a receptor complex. Int J Cancer 2006 118 : 1635 44.
112. Adhami VM, Siddiqui IA, Ahmad N, Gupta S, Mukhtar H. Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Res 2004 64 : 8715 22.
113. Zhou JR, Yu L, Zhong Y, Blackburn GL. Soy phytochemicals and tea bioactive components synergistically inhibit androgen-sensitive human prostate tumors in mice. J Nutr 2003 133 : 516 21.
114. Furstenberger G, Senn HJ. Insulin-like growth factors and cancer. Lancet Oncol 2002 3 : 298 302.
115. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000 92 : 1472 89.
116. Kaplan PJ, Mohan S, Cohen P, Foster BA, Greenberg NM. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res 1999 59 : 2203 9.
117. Fernandez PL, Hernandez L, Farre X, Campo E, Cardesa A. Alterations of cell cycle-regulatory genes in prostate cancer. Pathobiology 2002 70 : 1 10.
118. Davis JN, Day ML. The convergence of hormone regulation and cell cycle in prostate physiology and prostate tumorigenesis. Mol Biotechnol 2002 22 : 129 38.
119. Lee MH, Yang HY. Negative regulators of cyclin-dependent kinases and their roles in cancers. Cell Mol Life Sci 2001 58 : 1907 22.
120. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 2003 36 : 131 49.
121. Toogood PL. Cyclin-dependent kinase inhibitors for treating cancer. Med Res Rev 2001 21 : 487 98.
122. Lin JK, Liang YC, Lin-Shiau SY. Cancer chemoprevention by tea polyphenols through mitotic signal transduction blockade. Biochem Pharmacol 1999 58 : 911 5.
123. Gupta S, Hussain T, Mukhtar H. Molecular pathway for (-)- epigallocatechin-3-gallate-induced cell cycle arrest and apoptosis of human prostate carcinoma cells. Arch Biochem Biophys 2003 410 : 177 85.
124. Siddiqui IA, Adhami VM, Afaq F, Ahmad N, Mukhtar H. Modulation of phosphatidylinositol-3-kinase/protein kinase B- and mitogen-activated protein kinase-pathways by tea polyphenols in human prostate cancer cells. J Cell Biochem 2004 91 : 232 42.
125. Van de Sande T, De Schrijver E, Heyns W, Verhoeven G, Swinnen JV. Role of the phosphatidylinositol 3′-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells. Cancer Res 2002 62 : 642 6.
126. Yu R, Jiao JJ, Duh JL, Gudehithlu K, Tan TH, Kong AN. Activation of mitogen-activated protein kinases by green tea polyphenols: potential signaling pathways in the regulation of antioxidant-responsive element-mediated phase II enzyme gene expression. Carcinogenesis 1997 18 : 451 6.
127. Katiyar SK, Afaq F, Azizuddin K, Mukhtar H. Inhibition of UVB-induced oxidative stress-mediated phosphorylation of mitogen-activated protein kinase signaling pathways in cultured human epidermal keratinocytes by green tea polyphenol (-)-epigallocatechin-3-gallate. Toxicol Appl Pharmacol 2001 176 : 110 7.
128. Gasparian AV, Yao YJ, Kowalczyk D, Lyakh LA, Karseladze A, Slaga TJ, et al. The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. J Cell Sci 2002 115 : 141 51.
129. Ismail HA, Lessard L, Mes-Masson AM, Saad F. Expression of NF-kappaB in prostate cancer lymph node metastases. Prostate 2004 58 : 308 13.
130. Suh J, Rabson AB. NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon J Cell Biochem 2004 91 : 100 17.
131. Hodge JC, Bub J, Kaul S, Kajdacsy-Balla A, Lindholm PF. Requirement of RhoA activity for increased nuclear factor kappaB activity and PC-3 human prostate cancer cell invasion. Cancer Res 2003 63 : 1359 64.
132. Lessard L, Mes-Masson AM, Lamarre L, Wall L, Lattouf JB, Saad F. NF-kappa B nuclear localization and its prognostic significance in prostate cancer. BJU Int 2003 91 : 417 20.
133. Liao S, Umekita Y, Guo J, Kokontis JM, Hiipakka RA. Growth inhibition and regression of human prostate and breast tumors in athymic mice by tea epigallocatechin gallate. Cancer Lett 1995 96 : 239 43.
134. Siddiqui IA, Zaman N, Aziz MH, Reagan-Shaw SR, Sarfaraz S, Adhami VM, et al. Inhibition of CWR22Rnu1 tumor growth and PSA secretion in athymic nude mice by green and black teas. Carcinogenesis 2006 27 : 833 9.
135. Adhami VM, Malik A, Zaman N, Sarfaraz S, Siddiqui IA, Syed DN, et al. Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clin Cancer Res 2007 13 : 1611 9.
136. Limpens J, Schroder FH, de Ridder CM, Bolder CA, Wildhagen MF, Obermuller-Jevic UC, et al. Combined lycopene and vitamin E treatment suppresses the growth of PC-346C human prostate cancer cells in nude mice, J Nutr 2006 136 : 1287 93.
137. Venkateswaran V, Fleshner NE, Klotz LH. Synergistic effect of vitamin E and selenium in human prostate cancer cell lines. Prostate Cancer Prostatic Dis 2004 7 : 54 6.
138. Tokar EJ, Ancrile BB, Ablin RJ, Webber MM. Cholecalciferol (vitamin D3) and the retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) are synergistic for chemoprevention of prostate cancer. J Exp Ther Oncol 2006 5 : 323 33.
139. Heilbrun LK, Nomura A, Stemmermann GN. Black tea consumption and cancer risk: a prospective study. Br J Cancer 1986 54 : 677 83.
140. Jain MG, Hislop GT, Howe GR, Burch JD, Ghadirian P. Alcohol and other beverage use and prostate cancer risk among Canadian men. Int J Cancer 1998 78 : 707 11.
141. La Vecchia C, Negri E, Franceschi S, D'Avanzo B, Boyle P. Tea consumption and cancer risk. Nutr Cancer 1992 17 : 27 31.
142. Slattery ML, West DW. Smoking, alcohol, coffee, tea, caffeine, and theobromine: risk of prostate cancer in Utah (United States). Cancer Causes Control 1993 4 : 559 63.
143. Ellison LF. Tea and other beverage consumption and prostate cancer risk: a Canadian retrospective cohort study. Eur J Cancer Prev 2000 9 : 125 30.
144. Jian L, Xie LP, Lee AH, Binns CW. Protective effect of green tea against CaP: a case-control study in southeast China. Int J Cancer 2004 108 : 130 5.
145. Pisters KM, Newman RA, Coldman B, Shin DM, Khuri FR, Hong WK, et al. Phase I trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol 2001 19 : 1830 8.
146. Jatoi A, Ellison N, Burch AP, Sloan JA, Dakhil RS, Novotny P, et al. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 2003 97 : 1441 6.
147. Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 2006 66 : 1234 40.
148. Yang CS, Chen L, Lee MJ Balentine D, Kuo MC, Schantz SP. Blood and urine levels of tea catechins after ingestion of different amounts of green tea by human volunteers. Cancer Epidemiol Biomarkers Prev 1998 7 : 351 4.
149. Yang CS, Lee MJ, Chen L. Human salivary tea catechin levels and catechin esterase activities: implications in human cancer prevention studies. Cancer Epidemiol Biomarkers Prev 1999 8 : 83 9.
150. He YH, Kies C. Green and black tea consumption by humans: impact on polyphenol concentrations in feces, blood, and urine. Plant Foods Hum Nutr 1994 46 : 221 9.